| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 9 | AT 1 | 99.27 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 58 | AT 1 | 99.75 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 27 | AT 1 | 99.56 |
| Platelet Disorders and Treatments | Lifetime | 77 | AT 1 | 99.17 |
| Hemophilia Treatment and Research | Lifetime | 28 | AT 1 | 99.22 |
| Central Venous Catheters and Hemodialysis | Lifetime | 79 | AT 1 | 99.21 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 403 | AT 4 | 98.98 |
| Cardiovascular Issues in Pregnancy | Lifetime | 177 | AT 3 | 98.25 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 299 | AT 5 | 97.45 |
| Blood groups and transfusion | Lifetime | 415 | AT 7 | 97.32 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 378 | AT 7 | 97.28 |
| Acute Myocardial Infarction Research | Lifetime | 817 | AT 5 | 97.62 |
| Cardiac tumors and thrombi | Lifetime | 569 | AT 4 | 95.37 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 277 | AT 4 | 94.86 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 378 | AT 2 | 93.22 |
| Blood disorders and treatments | Lifetime | 714 | AT 13 | 93.12 |
| Hemostasis and retained surgical items | Lifetime | 644 | AT 14 | 80.61 |
| Intramuscular injections and effects | Lifetime | 924 | AT 7 | 62.47 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 72 | AT 1 | 99.01 |
| Blood Coagulation and Thrombosis Mechanisms | 2021-2025 | 15 | AT 1 | 98.30 |
| Platelet Disorders and Treatments | 2021-2025 | 41 | AT 1 | 97.95 |
| Hemophilia Treatment and Research | 2021-2025 | 18 | AT 1 | 98.81 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 349 | AT 5 | 92.44 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 479 | AT 4 | 89.82 |
| Central Venous Catheters and Hemodialysis | 2021-2025 | 357 | AT 2 | 87.24 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 269 | AT 3 | 85.29 |
| Blood groups and transfusion | 2021-2025 | 588 | AT 2 | 80.49 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 259 | AT 4 | 78.57 |
| GDF15 and Related Biomarkers | 2021-2025 | 214 | AT 5 | 73.58 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 706 | AT 7 | 76.58 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 959 | AT 13 | 72.41 |
| Blood properties and coagulation | 2021-2025 | 620 | AT 8 | 63.79 |
| Blood disorders and treatments | 2021-2025 | 932 | AT 6 | 59.62 |
| Intramuscular injections and effects | 2021-2025 | 167 | AT 2 | 62.02 |
| Apelin-related biomedical research | 2021-2025 | 773 | AT 10 | 31.33 |
